Molecular Imaging

Molecular imaging (also called nuclear medicine or nuclear imaging) can image the function of cells inside the body at the molecular level. This includes the imaging modalities of positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. How does PET and SPECT imaging work? Small amounts of radioactive material (radiopharmaceuticals) injected into a patient. These can use sugars or chemical traits to bond to specific cells. The radioactive material is taken up by cells that consume the sugars. The radiation emitted from inside the body is detected by photon detectors outside the body. Computers take the data to assemble images of the radiation emissions. Nuclear images may appear fuzzy or ghostly rather than the sharper resolution from MRI and CT.  But, it provides metabolic information at a cellular level, showing if there are defects in the function of the heart, areas of very high metabolic activity associated with cancer cells, or areas of inflammation, data not available from other modalities. These noninvasive imaging exams are used to diagnose cancer, heart disease, Alzheimer’s and Parkinson’s disease, bone disorders and other disorders. 

Is preoperative PET/CT necessary for advanced colon cancer?

PET/CT prior to hepatic resection for advanced colorectal cancer patients with liver metastases may not be as beneficial as previously thought, according to a study published today in the Journal of the American Medicine Association.

Thumbnail

Breast PET passes tech evaluation with flying colors

Dedicated breast PET appears to be performing up to National Electrical Manufacturers Association (NEMA) standards, according to a study looking into the performance specifics of the emerging technology published May 8 in the Journal of Nuclear Medicine.

Thumbnail

Northwest Medical to build radioisotope facility to meet half of U.S. need

Oregon-based radioisotope technology company Northwest Medical Isotopes (NWMI) announced late last week that there are plans to construct a facility for radioisotope production at the University of Missouri-owned Discovery Ridge Research Park in Columbia, Mo.

Thumbnail

Early menopause may trigger cognitive decline

Women who experience premature menopause either due to surgical treatment or reproductive organ failure may have a higher risk of cognitive problems later in life, according to a large, multisite study in France published May 7 in the international journal of obstetrics and gynecology, BJOG.

Thumbnail

AC Immune partners with Piramal to commercialize tau agents

Piramal Imaging announced today that the company has settled into a global license agreement with Swiss bioresearch firm AC Immune for further development and commercialization of tau-protein PET agents designed to aid in the diagnosis of neurodegenerative disease, including Alzheimer’s disease (AD).

Imaging Endpoints teams up with AG Mednet on clinical trials

Boston-based AG Mednet announced yesterday that the software company would be partnering with board-certified radiologists from Imaging Endpoints to improve the latter's clinical trial submission quality and compliance.

Thumbnail

CMS reiterates ruling on radiopharmaceutical prep and ASC imaging

The Centers for Medicare & Medicaid Services (CMS) is projected to publish a final rule on “burdensome” regulations regarding imaging in ambulatory surgical centers (ASC) and radiopharmaceutical preparation in hospitals on May 12.

Navidea: Revenue from Lymphoseek leaps 83% in first quarter

Navidea Biopharmaceuticals, developers of Lymphoseek and novel NAV4694 announced its first quarter 2014 financial report Wednesday including word of $752,000 revenue over absolutely zero revenue for that period last year.